ClinicalTrials.gg
WithdrawnNCT04398680DREAMM 13Updated Dec 4, 2025

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

A Phase 1 interventional study of Belantamab mafodotin in Multiple Myeloma, sponsored by GlaxoSmithKline. Withdrawn at 18 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Enrollment
47th of 49
0 · median 50
Started
2021
with 10 others
Phase 1
11 of 49
3 open now
Registered
9th of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 47th largest by enrollment, is one of 11 that started in 2021, is one of 11 in phase 1, and was the 9th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants with normal hepatic function.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • DREAMM 13
  • Belantamab mafodotin monotherapy
  • Hepatic impairment
  • Normal hepatic function
  • Relapsed or refractory multiple myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are capable of giving signed which includes compliance with the requirements and restrictions listed in the Informed Consent Form.
  • Male and/or female must be 18 years of age or older, at the time of signing the informed consent.
  • performance status 0-2.
  • Participants with or cytologically confirmed diagnosis of multiple myeloma, as defined in International Myeloma Working Group criteria: Has failed at least 1 prior line of anti-myeloma
  • Participants has with at least one of the following: Serum M-protein greater than or equal to (>=)0.5 grams per deciliter (g/dL) >=5 grams per liter [g/L]); Urine M-protein >=200 milligram per 24 hours (mg/24 hr); and Serum free light chain assay: Involved free light chain level >=10 milligrams per deciliter (mg/dL) (>=100 milligrams per liter [mg/L]); abnormal serum free light chain ratio (\<0.26 or >1.65); participants with plasmacytoma and otherwise non-measurable disease
  • Participants with a history of SCT are eligible for study participation provided the following eligibility criteria are met: 1. Transplant was >100 days prior to study enrollment, 2. No active infection(s), and 3. Participant meets the remainder of the eligibility criteria outlined in this protocol.
  • Participants with adequate organ system functions as defined below: >=1.0 times 10\^9/liter (L); >=8.0 g/dL (or 4.9 millimoles per liter); >= 75 times 10\^9/L; Serum and : Group 1 (normal) serum bilirubin and aspartate aminotransferase \<= (ULN); Group 2 (moderate) serum bilirubin >1.5-3 times ULN and any aspartate aminotransferase; alanine aminotransferase \<=5 ULN; Estimated >=30 milliliter per minute per 1.73 meter square (mL/min/m\^2); Urine dipstick for protein or Albumin/creatinine ratio (from spot urine) negative/trace (if >=1+ only eligible if confirmed \<=500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void; and by echocardiograms >=45 percent (%).
  • Main additional inclusion criteria in Group 1 (matched control participants): Matched to at least one moderate hepatic impaired participant by Baseline albumin levels (+/-10%) and Baseline weight (+/-20%).
  • Female participants: use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and not a woman of (WOCBP) or is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year).
  • Male participants: Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants are eligible to participate if they agree to the following from the time of first dose of study until 6 months after the last dose of study treatment.
  • Participants with a history of virus and/or virus and exposure are eligible under specific conditions.

Exclusion criteria

Exclusion Criteria:

  • Active plasma cell leukemia at the time of screening. symptomatic amyloidosis, active polyneuropathy, organomegaly, endocrinopathy, myeloma protein and skin changes, Waldenstroem macroglobulinemia.
  • Participants had a prior SCT.
  • Prior belantamab mafodotin therapy if given within the last 90 days.
  • Systemic active infection requiring treatment
  • Any unresolved toxicity >=Grade 2 from previous treatment except for alopecia, or peripheral neuropathy up to Grade 2.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities except hepatic impairment) that could interfere with participant's safety, obtaining or compliance to the study procedures.
  • Current unstable liver or biliary disease per investigator assessment defined by the sudden onset of, or changes in: ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, in the last 14 days prior to the first dose.
  • Participants with will be excluded unless the following criteria can be met: If the participant is hepatitis B core antibody (HbcAb) positive or hepatitis B surface antigen (HbsAg) negative, then hepatitis B virus (HBV) deoxyribonucleic acid (DNA) should be undetectable at the time of screening; If HbsAg+ at screening or \<=3 months prior to first dose of study treatment, then HBV DNA should be undetectable, highly effective antiviral treatment should be started ≥4 weeks prior to first dose of study treatment. Participants with cirrhosis are excluded.
  • Positive antibody test result or positive hepatitis C ribonucleic acid test result at Screening or within 3 months prior to first dose of study treatment unless the participant can meet the following criteria: RNA test negative and/or Successful anti-viral treatment (usually 8 weeks duration) is required, followed by a negative HCV RNA test after a of at least 4 weeks prior to first dose.
  • Participants with Gilbert's syndrome.
  • -Participants with previous or concurrent invasive other than MM are excluded, unless the prior malignancy has been considered medically stable for at least 1 year. The participant must not be receiving active therapy, other than hormonal therapy for this disease.
  • Evidence of cardiovascular risk including any of the following: Evidence of current clinically significant untreated arrhythmias, including clinically significant abnormalities including second degree (Mobitz Type II) or third degree atrioventricular block; History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening; Class III or IV heart failure as defined by the functional classification system; and Uncontrolled hypertension.
  • Known infection, unless the participant can meet all of the following criteria: Established anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load \<400 copies/mL prior to first dose; CD4+ T-cell (CD4+) counts ≥350 cells/ L and no history of AIDS-defining opportunistic infections within the last 12 months.
  • Current corneal epithelial disease except for mild punctuate keratopathy.
  • Participant is a woman who is pregnant or breastfeeding.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Part 1, Group 1: Participants with normal hepatic function

    Participants with normal hepatic function (Serum bilirubin and Aspartate aminotransferase \[AST\] less than or equal to \[\<=\] Upper limit of normal \[ULN\]) will be administered with Belantamab mafodotin

    Drug: Belantamab mafodotin

  • Experimental
    Part 1, Group 2: Participants with moderate hepatic impairment

    Participants with moderate hepatic impairment (Serum bilirubin greater than \>1.5 - 3 times ULN and any AST) will be administered with Belantamab mafodotin

    Drug: Belantamab mafodotin

  • Experimental
    Part 2,Group 3: Participants with severe hepatic impairment

    Participants with severe hepatic impairment (Serum bilirubin \>3 times ULN and any AST) will be administered with Belantamab mafodotin

    Drug: Belantamab mafodotin

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1 and Part 2: Maximum observed plasma concentration (Cmax) of Belantamab Mafodotin

    Time frame: Up to 48 months

  2. Part 1 and Part 2: Time to Cmax (Tmax) of Belantamab Mafodotin

    Time frame: Up to 48 months

  3. Part 1 and Part 2: Concentration at the end of infusion (C-EOI)

    Time frame: Up to 48 months

  4. Part 1 and Part 2: Predose plasma concentration (Ctrough) of Belantamab Mafodotin

    Time frame: Up to 48 months

  5. Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval)

    Time frame: Up to 48 months

  6. Part 1 and Part 2: Last time point where the concentration is above the limit of quantification (Tlast) of Belantamab Mafodotin

    Time frame: Up to 48 months

  7. Part 1 and Part 2: Cmax of total monoclonal antibody (mAb)

    Time frame: Up to 48 months

  8. Part 1 and Part 2: Tmax of total mAb

    Time frame: Up to 48 months

  9. Part 1 and Part 2: C-EOI of total mAB

    Time frame: Up to 48 months

  10. Part 1 and Part 2: Ctrough of total mAb

    Time frame: Up to 48 months

  11. Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval)of total mAb

    Time frame: Up to 48 months

  12. Part 1 and Part 2: Tlast of total mAb

    Time frame: Up to 48 months

  13. Part 1 and Part 2: Cmax of Cys Monomethyl Auristatin F (cys-mcMMAF)

    Time frame: Up to 48 months

  14. Part 1 and Part 2: Tmax of cys-mcMMAF

    Time frame: Up to 48 months

  15. Part 1 and Part 2: C-EOI of cys-mcMMAF

    Time frame: Up to 48 months

  16. Part 1 and Part 2: AUC(0-168 hours) of cys-mcMMAF

    Time frame: Up to 48 months

  17. Part 1 and Part 2: tlast of cys-mcMMAF

    Time frame: Up to 48 months

Secondary outcomes

  1. Part 1 and Part 2: Change from Baseline in Vital Signs- Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) (millimeters of mercury [mmHg])

    Time frame: Baseline and up to 4 years

  2. Part 1 and Part 2: Change from Baseline in Vital Sign- Heart rate (beats per minute)

    Time frame: Baseline and up to 4 years

  3. Part 1 and Part 2: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Up to 4 years

  4. Part 1 and Part 2: Number of participants with toxicity grading for hematology parameters

    Time frame: Up to 4 years

  5. Part 1 and Part 2: Number of participants with toxicity grading for clinical chemistry parameters

    Time frame: Up to 4 years

  6. Part 1 and Part 2: Number of participants with toxicity grading for urine parameters

    Time frame: Up to 4 years

07

Study locations

18 sites
  • GSK Investigational Site
    Tucson, Arizona 85724, United States
  • GSK Investigational Site
    Beverly Hills, California 90211, United States
  • GSK Investigational Site
    Plantation, Florida 33322, United States
  • GSK Investigational Site
    Wichita, Kansas 67214, United States
  • GSK Investigational Site
    Baltimore, Maryland 21201-1595, United States
  • GSK Investigational Site
    Monroeville, Pennsylvania 15146, United States
  • GSK Investigational Site
    The Woodlands, Texas 77380, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53233, United States
  • GSK Investigational Site
    Athens, 10676, Greece
  • GSK Investigational Site
    Daegu, 41944, South Korea
  • GSK Investigational Site
    Hwasun, 58128, South Korea
  • GSK Investigational Site
    Incheon, 405-760, South Korea
  • GSK Investigational Site
    Jeonju, 561-172, South Korea
  • GSK Investigational Site
    Pusan, 49241, South Korea
  • GSK Investigational Site
    Seoul, 03080, South Korea
  • GSK Investigational Site
    Seoul, 06591, South Korea
  • GSK Investigational Site
    Seoul, 120-752, South Korea
  • GSK Investigational Site
    Suwon Kyunggi-do, 16499, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2021 (actual). Primary completion is estimated for Nov 2025, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2020
First posted
May 21, 2020
StartActual
Apr 20, 2021
Primary completionEst.
Nov 4, 2025
CompletionEst.
Nov 4, 2025
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04398680
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 21, 2020
Start date
Apr 20, 2021
Primary completion
Nov 4, 2025 (estimated)
Completion
Nov 4, 2025 (estimated)
Last update
Dec 4, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belantamab mafodotin

Start the discussion